MAG and Erythema: Among placebo recipients there was a trend towards increased reactogenicity between prime (EP) and boost (standard IM) injections (p = 0.063 for both pain and/or tenderness, and erythema and/or induration)—suggesting increased injection site symptoms were an effect of EP as opposed to the presence of HIV-MAG vaccine or IL-12 pDNA adjuvant.